AZ-1495

N/A

Report date: 2025/01/26 17:06:52
NME

Base Information

Drug NameAZ-1495
Drug Alias NameIRAK4 inhibitor (AstraZeneca/University of California San Francisco/University of British Columbia)AZ-1495
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsCentral Nervous System NeoplasmsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Pharmaceuticals Lp
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceuticals LpUniversity Of California San FranciscoThe University Of British Columbia
Inactive CompaniesN/A
Active IndicationsCentral Nervous System NeoplasmsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A